CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance TestingBusiness Wire • 04/28/26
CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation's 46th Annual MeetingBusiness Wire • 04/21/26
CareDx Launches AlloSeq Nano for High-Resolution Rapid HLA TypingZacks Investment Research • 04/21/26
CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read SequencingBusiness Wire • 04/20/26
Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product divisionGlobeNewsWire • 04/16/26
CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial ResultsBusiness Wire • 04/15/26
CareDx Introduces VANTx AI Platform for Complex Transplant DatasetsZacks Investment Research • 03/12/26
CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant DatasetsBusiness Wire • 03/05/26
CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial OfficerBusiness Wire • 02/24/26
CareDx to Participate in the Raymond James 47th Annual Institutional Investors ConferenceBusiness Wire • 02/18/26
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCTZacks Investment Research • 02/16/26
CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy TranscriptSeeking Alpha • 02/12/26
CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell TherapyBusiness Wire • 02/12/26
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026Business Wire • 02/10/26